Acarbocin

Main information

  • Trade name:
  • Acarbocin 50 mg Tablet
  • Dosage:
  • 50 mg
  • Pharmaceutical form:
  • Tablet
  • Units in package:
  • Blister pack, 90 tablets
  • Class:
  • Prescription
  • Prescription type:
  • Prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • Bayer AG

Documents

Localization

  • Available in:
  • Acarbocin 50 mg Tablet
    New Zealand
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • Indicated for the additional treatment of insulin dependent and non-insulin dependent diabetes mellitus in association with diet.

Other information

Status

  • Source:
  • Medsafe - Medicines Safety Authority - New Zealand
  • Authorization number:
  • 15400
  • Authorization date:
  • 26-03-2012
  • Last update:
  • 27-09-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

1

Acarbocin

NewZealandConsumer MedicineInformation

Acarbocin

Acarbose50mg& 100mg tablets

What is inthis leaflet

Please readthisleafletcarefullybeforeyoustarttakingAcarbocin.

ThisleafletanswerssomecommonquestionsaboutAcarbocin.Itdoesnotcontainall

theavailableinformation.Themostup-to-dateConsumerMedicineInformationcanbe

downloadedfromwww.medsafe.govt.nz.

Readingthisleafletdoesnottaketheplaceoftalkingto yourdoctororpharmacist.

Allmedicineshaverisksandbenefits.Yourdoctorhasweighedtherisksofyoutaking

Acarbocinagainstthebenefitsthismedicineisexpectedto haveforyou.

Ifyouhaveanyconcernsabouttakingthismedicine,askyourdoctoror

pharmacist.

Keep thisleafletwiththemedicine.

Youmaywanttoreaditagain.

WhatAcarbocinisusedfor

Acarbocincontainstheactiveingredientacarbose.Itbelongstoaclassofmedicines

called“alphaglucosidaseinhibitors”andithelpstocontrolyourbloodsugarlevelsin

conjunctionwithdiet,exercise,weightlossandothermeasuresbyslowingdownthe

digestionandabsorptionofcarbohydrates (complexsugars)fromyourdiet.Thisreduces

theabnormallyhigh blood sugarlevelsthatoccuraftereachmeal.

Acarbocinisusedforthetreatmentofdiabetes(bothnon-insulinandinsulindependent)

in association with diet.

Yourdoctormayhave prescribedthismedicineforanotherreason.

Askyourdoctorifyouhaveanyquestionsaboutwhyithasbeenprescribedfor

you.

Acarbocinisavailable onlywith adoctor'sprescription.

Acarbocinisnotaddictive.

2

Acarbocin

BeforeyoutakeAcarbocin

Acarbocinisnotsuitableforeveryone.

When you must nottakeit

Do nottakeAcarbocinifyou:

areunder18yearsofage

have aseverekidneydisorder

have aliverdisorder

sufferfromintestinalobstruction,inflammation orulcerationofthebowel,e.g.

ulcerative colitisorCrohn'sdisease

have ahernia orhave had previousabdominalsurgery.Ifso,consultyour

doctorfirst.

DonottakeAcarbocinifyouareallergictoanymedicinecontainingacarboseor

anyoftheingredientslistedattheend ofthisleaflet.

Do nottakeitaftertheexpirydate (‘EXP’)printedonthepack.

Ifyoutakeitaftertheexpirydate haspassed,itmaynotworkaswell.

Do nottakeitifthepackagingistornorshows signsoftampering.

Ifyouarenotsurewhetheryoushouldstarttakingthismedicine,talktoyour

doctororpharmacist.

Beforeyoustarttotake it

Tellyourdoctororpharmacistifyouhaveallergiestoanyothermedicines,foods,

preservativesordyes.

Do nottakethismedicineifyouarepregnantorintendto becomepregnant.

Thesafetyoftheuseofthismedicineinwomenwhoarepregnantormaybecome

pregnanthasnotbeenestablished.Acarbocinisnotrecommendedforuseduring

pregnancy,unless youandyourdoctorhave discussed therisksandbenefitsinvolved.

Do notbreast-feedifyouaretakingthismedicine.

TheactiveingredientinAcarbocinpassesintobreastmilkandthereisapossibilitythat

yourbabymaybeaffected.

Ifyouhavenottoldyourdoctororpharmacistaboutanyoftheabove,tellthem

before youstarttakingAcarbocin.

Taking othermedicines

Tellyourdoctororpharmacistifyouaretaking anyothermedicines,includingany

thatyougetwithoutaprescriptionfromyourpharmacy,supermarketorhealth

food shop.

Tellanyhealthprofessionalwhoisprescribinganewmedicineforyouthatyou

aretakingAcarbocin.

3

Acarbocin

SomemedicinesandAcarbocinmayinterfere with each other.These include:

charcoal(usedfortreatmentofdigestive complaints,poisoningordrug overdose)

digestive enzyme preparations (e.g.pancreatin andamylase)

neomycin(antibiotic used before bowelsurgery)

colestyramine(usedfortreatingitchinessresultingfromliverproblems,high

cholesterolordiarrhoea)

digoxin (usedfortreatmentofheartfailureorheartrhythmproblems)

diureticsorcalciumchannelblockers(usedinthetreatmentofhighblood

pressure)

corticosteroids(usedtotreatinflammation)

phenytoin (usedtotreatepilepticfits)

phenothiazine(used totreatmentalhealth)

thyroid medicines

femalesexhormone(oestrogens),oralcontraceptives

nicotinicacid (usedtolowerblood cholesterol)

medicinescalled“sympathomimetics”,suchasepinephrineandnorepinephrine;

thesemaybeusedinthetreatmentofcardiacarrest,severedropinblood

pressureorprematurelabour

isoniazid (usedtotreattuberculosis).

TheabovemedicinesmaybeaffectedbyAcarbocin,ormayaffecthowwellitworks.

YoumayneeddifferentamountsofAcarbocin,ortakeitatdifferenttimes,oryoumay

needtotakedifferentmedicines.

Yourdoctorandpharmacisthavemoreinformationonmedicinestobecarefulwithor

avoidwhile takingAcarbocin.

HowtotakeAcarbocin

Readthelabelcarefullyandfollowalldirectionsgiventoyoubyyourdoctorand

pharmacist.

Theymaydifferfromtheinformationcontained inthisleaflet.

Ifyoudonotunderstandtheinstructionsonthepack,askyourdoctoror

pharmacistforhelp.

When and how to takeit

Take thetabletsasprescribed byyourdoctor.

Thiswillnormallybeone ortwo tabletstakenwith breakfast,lunch and dinner.

When youfirststartyourtreatment,yourdoctormayrecommendthatyoutakeyour

tabletsonce ortwice aday,beforeincreasing yourdosetothreetimesaday.

Chewthetabletswiththefirstfewmouthfulsoffood.

Ifyouprefernottochewthetablets,thenswallowthemwholewithalittleliquid

immediatelybeforethemeal.

4

Acarbocin

Askyourdoctorifyouareunsureofthecorrectdoseforyou.

Theywilltellyouexactlyhowmuchtotake.Thisdependsonyourconditionandwhether

ornotyouaretaking anyothermedicines.

How longto take it

Continuetakingthemedicineforaslongasyourdoctortells youto.

Acarbocinhelpstocontrolyourcondition,butdoesnotcureit.Itisimportanttokeep

takingthemedicineevenifyoufeelwell.

IfyouareunsurewhetheryoushouldstoptakingAcarbocin,talkto yourdoctoror

pharmacist.

If youforgetto takeit

IfyouforgettotakeAcarbocinatthetimeyouaresupposedto,donottakethe

tablets betweenmeals.

WaituntilitistimeforyoutotakeyournextdoseandtakeAcarbocinwithyourmealand

continue asbefore.

Do nottryto makeupformisseddoses bytakingmorethan onedose atatime.

Thismayincreasethechance ofgettinganunwantedsideeffect.

Ifyouarenotsurewhattodo,askyourdoctororpharmacist.

While youare takingAcarbocin

Things you must do

Ifyouareabouttobestartedonanynewmedicine,tellyourdoctorand

pharmacistthatyouaretakingAcarbocin.Likewise,tellanyotherdoctors,

dentists andpharmacistswhoaretreatingyou thatyouaretakingthismedicine.

Ifyoubecomepregnantwhiletakingthismedicine,tellyourdoctorimmediately.

Seeyourdoctorifyoufeelthatyourconditionisnotimprovingorisgettingworse.

Things you must not do

Donotgiveyourmedicinetoanyoneelse,eveniftheyhavethesameconditionas

you.

Thismedicineisonlyintendedforthepersonithas beenprescribedfor.

DonottakeAcarbocintotreatanyothercomplaintsunlessyourdoctortellsyou

to.

DonotstoptakingAcarbocinorchangethedosagewithoutcheckingwithyour

doctor.

5

Acarbocin

Things tobe carefulof

Treatinghypoglycaemia ("hypos"orlowblood sugar)

Asadiabeticyoumayalsobereceivingothermedicinesforyourdiabetes.IfAcarbocin

isprescribedforyouinadditiontootherantidiabeticmedicinessuchassulfonylureasor

metformintocontrolyourdiabetes,yourdoctormayneedtoadjustthedosagesofthese

medicinestoavoid theoccurrenceof"hypos".

Hypoglycaemiaisapotentiallyseriouscondition.Lowbloodsugarlevelscancause

someofthefollowingsymptoms:

double vision

confusion

slurredspeech

faintness

trembling

palpitations (abnormalawareness ofyourown heartbeat).

When takingAcarbocin togetherwith thesemedicines,donottreata "hypo"with ordinary

sugar(sucrose).Itwillnotworkfastenough. Instead,youshouldtakesome“glucose”

(alsoknownasdextrose)tablets,honey,syruporsweets,whichshouldbeavailable

fromyourlocalchemist.

Drivingand usingmachines

Acarbocindoesnotaffectyourabilitytodriveoroperatemachineryiftakenonitsown.

However,youmayexperiencelowbloodsugarlevelsifyoutakeotheranti-diabetic

agentsatthesametime,suchassulfonylureasormetformin.Thismayaffectyourability

to drive oroperatemachinerysafely.

Incaseof overdose

If youtake toomuch

IfyouhavetakentoomanyAcarbocintablets,avoidfoodsordrinkscontaining

carbohydratesandtelephoneyourdoctor,orthePoisonsInformationCentre

(telephone0800POISONor0800764 766)foradvice.

When Acarbocin is takenwith drinksand/ormealscontainingcarbohydrates,overdosage

canleadtodiarrhoeaandotherintestinalsymptomssuchasflatulence(wind)and

abdominalcramps.

Side effects

Tellyourdoctororpharmacistassoonaspossibleifyoudonotfeelwellwhile

youaretakingAcarbocin.

Likeallmedicines,Acarbocinmayoccasionallycausesideeffectsinsomepeople.

Thesesideeffectsaremorecommonatthestartofthetreatment,butsomemaypersist

ordevelopaftertreatment,orwhenthedosageofAcarbocinisadjustedbyyourdoctor.

6

Acarbocin

Sometimestheyareserious,mostofthetimetheyarenot.Youmayneedmedical

attentionifyougetsomeofthesideeffects.

Askyourdoctororpharmacistto answeranyquestionsyoumayhave.

DuringthefirstfewdaysorweeksoftreatmentwithAcarbocinyoumayhavemore

flatulence(wind),abdominal"rumbling"noises,afeelingoffullnessand,lesscommonly,

stomachcrampsand/orindigestion.Youmayalsopasssofterstoolsorhavediarrhoea,

particularlyifyouhaveeatenfoodscontainingsugar.Normallythesesymptomswill

disappearifyoucontinuetreatmentandkeeptoyourprescribeddiet.Thesesymptoms

maygetworseifyoudonotkeeptoyourprescribeddiet.

Ifyoursymptomspersistformorethan2or3days,oriftheyaresevere,consult

yourdoctor,particularlyin thecaseofdiarrhoea.

Donottakeantacidstotreatthesesymptoms,astheyareunlikelytogiveyouany

relief.

Lesscommonsideeffectsincludehypoglycaemia("hypos"orlowbloodsugar),nausea,

vomiting,increasedappetite,dizzinessandlossofappetite.Thesesideeffectsgenerally

occurwhenAcarbocinistakentogetherwith sulfonylureasormetformin.

RarereactionsthathavebeenreportedforAcarbocintreatmentincludeinflammationof

theliver(hepatitis),swellingfromfluidretention,intestinalobstruction,decreasein

plateletcount,jaundice(yellowingoftheskin)andskinreactionssuchasredness,rash

andurticaria(hives).Acarbosemaycauseanincreaseintheresultsofcertainliver

functiontests.Theseeffectsgoawaywhen treatmentisstopped.

Tellyourdoctororpharmacistifyounoticeanythingelsethatismakingyoufeel

unwell.

Othersideeffectsnotlistedabove mayalso occurin some patients.

Do notbealarmedbythislistofpossiblesideeffects.

Youmaynotexperienceanyofthem.

AftertakingAcarbocin

Storage

Keepyourtabletsinthepackuntilitistimetotakethem.

Ifyoutakethetabletsoutofthepacktheymaynotkeepwell.

KeepAcarbocinina cooldryplacewherethetemperaturestays below25°C.

Donotstoreitoranyothermedicineinthebathroom,nearasink,oronawindow

sill.Do notleave itinthecar.

Heatand dampcandestroysomemedicines.

Keep itand anyothermedicinewherechildren cannotreachit.

Alockedcupboardatleastone-and-a-halfmetresabovethegroundisagoodplaceto

storemedicines.

7

Acarbocin

Do notkeepAcarbocinpastits expirydate.

Disposal

Returnanyunusedmedicineandanymedicinepastitsexpirydate(asshownon

thelabelling)to yourpharmacy.

Product description

What itlooks like

Acarbocinisavailable inblisterpacksof90tablets.

50mg tablets:round,biconvex,whitetooff- whitetabletswithbossing“ACA50”onone

side.

100 mg tablets:round,biconvex,whitetooff-whitetabletswithascore-lineononeside

and bossing“ACA100”ontheotherside.

Ingredients

Active ingredient:

acarbose

Inactive ingredients:

cellulose –microcrystalline

silica –colloidalanhydrous

magnesiumstearate

starch –pregelatinisedmaize.

Acarbocindoesnotcontain lactose,sucrose,tartrazineoranyotherazo dyes.

Sponsor details

Boucher&Muir(NewZealand)tradingasBNMGroup

39Anzac Road

Browns Bay

Auckland 0753

Ph:0800565 633

Date ofpreparation

Thisleafletwas preparedon29August2013.

3-1-2019

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Due to a potential manufacturing defect the lights may overheat, posing a burn and fire hazard.

Health Canada

21-12-2018

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, LLC of Eden Prairie, MN is recalling 10 oz Nutty Choco Pop Gift Box, 50 oz. Holiday Crowd Pleaser and 50 oz. Crowd Pleaser, because it may contain undeclared Almond and Cashew Tree Nut. People who have an allergy or severe sensitivity to Almonds and Cashews run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

29-11-2018

ANSES Newsletter in English - N°50 - November 2018

ANSES Newsletter in English - N°50 - November 2018

France - Agence Nationale du Médicament Vétérinaire

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

25-7-2018

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

Associated Milk Producers Inc. (AMPI) of New Ulm, Minn., is recalling dry whey powder packaged in 50-pound and 25-kg bags that were produced at the cooperative’s Blair, Wis., dry whey plant from May 1-5, 2018; May 24-29, 2018; June 2-5, 2018; and June 7-14, 2018 due to the potential to be contaminated with Salmonella. This is a precautionary recall. All products shipped to the marketplace tested negative for Salmonella.

FDA - U.S. Food and Drug Administration

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

7-12-2018


Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Acarbose: List of nationally authorised medicinal products - PSUSA/0000017/201803

Europe - EMA - European Medicines Agency

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

19-9-2018

Targretin (Eisai GmbH)

Targretin (Eisai GmbH)

Targretin (Active substance: bexarotene) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6098 of Wed, 19 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/326/T/50

Europe -DG Health and Food Safety

4-6-2018

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Active substance: apixaban) - Centralised - 2-Monthly update - Commission Decision (2018)3616 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2148/II/50

Europe -DG Health and Food Safety